Flipped Learning in Nursing Education

January 16, 2026 updated by: Dilek Erden, Namik Kemal University

THE IMPACT OF CANCER SCREENING TRAINING, CONDUCTED USING A CHATGPT-SUPPORTED FLIPPED LEARNING MODEL, ON NURSING STUDENTS' ACADEMIC KNOWLEDGE, LEARNING MOTIVATION, AND CLASSROOM ENGAGEMENT

This study aims to examine the effects of cancer screening training, conducted using a ChatGPT-based flipped learning model, on knowledge, learning motivation, and class participation.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Enrolling by invitation

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Methods: A randomized controlled trial was conducted with 46 intervention and 46 control groups. In the study, a training program based on traditional flipped learning and a ChatGPT-based flipped learning model for cancer screenings is applied. Data will be collected using the Knowledge Form, Cancer Screening Knowledge Scale, Higher Education Learning Motivation Scale, and Class Participation Scale.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
60

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey (Türkiye)
    • Suleymanpasa
      • Tekirdağ, Suleymanpasa, Turkey (Türkiye), 59030
        • Tekirdağ Namık Kemal University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Students who have taken courses in fundamentals of nursing, internal medicine nursing, physiology, pathology, and computer science, but have not taken a course in oncology nursing,
  • Third-year students,
  • Those who have voluntarily agreed to participate in the study.

Exclusion Criteria:

  • Students who were not third-year students,
  • Those who had not taken one of the following courses: fundamentals of nursing, internal medicine nursing, physiology, pathology, computer science, oncology nursing,
  • Those who did not volunteer to participate in the research were excluded from the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Intervention group- ChatGPT Flipped Learning
ChatGPT-Based Flıpped Learnıng Model
Other: ChatGPT-Based Flıpped Learning Model
Training group based on ChatGPT-based flipped learning model
Placebo Comparator: Control Group- Traditioanl Flipped Learning
Traditional Flıpped Learnıng Model
Other: Traditional Flıpped Learning Model
Training group based on traditional flipped learning model

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Cancer Screening Knowledge Scale
Time Frame: 4 weeks
This scale consists of 25 items and 3 sub-dimensions. The sub-dimensions are not specifically named. The first sub-dimension contains 10 items (items 8, 17-23, 25, 28), the second sub-dimension contains 9 items (items 4, 5, 7, 10, 12, 13, 15, 16, 27), and the third sub-dimension contains 6 items (items 1-3, 9, 11, 24). The scale is a three-point rating scale. The scale is answered on a scale of 1 to 3, with "1: True, 2: False, 3: I don't know". When calculating the scale score, "True" answers are worth 1 point, and "False" and "I don't know" answers are worth 0 points. The lowest possible score on the scale is 0, and the highest is 25. When calculating the scale score, the three items with negative connotations (Items 2, 11, 24) should be reverse-coded. The order of the items on the scale is not important; researchers may use a mixed order. There is no cutoff point for the scale score.
4 weeks

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Learning Motivation Scale in Higher Education
Time Frame: 4 weeks
The scale consisting of 23 items on a 3-point Likert scale, participants are given scores of Disagree (1), Don't Know (2), and Agree (3) for each question in the Learning Motivation Scale in Higher Education. The lowest possible score is 23 and the highest is 69. In the reliability studies of the scale, the Cronbach alpha coefficient of the learning objectives sub-dimension was calculated as 0.83, the avoidance objectives sub-dimension as 0.87, and the approach objectives sub-dimension as 0.82.
4 weeks

Other Outcome Measures

Other Outcome Measures

For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Classroom Engagement Scale
Time Frame: 4 weeks
The scale consisting of 15 items and 3 sub-dimensions on a 5-point Likert scale, participants are given scores for each question on a scale of 1 (Not Appropriate at all), 2 (Not Appropriate), 3 (Somewhat Appropriate), 4 (Appropriate), and 5 (Completely Appropriate). The scale includes sub-dimensions of Cognitive participation, Emotional participation, and Behavioral participation. In reliability studies of the scale, the Alpha value was found to be 0.93.
4 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Namik Kemal University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: DİLEK ERDEN, Namik Kemal University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
December 1, 2025

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
January 30, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
February 15, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
December 22, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 16, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
January 20, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
January 20, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 16, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
January 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • DERDEN-4

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

I can share it with researchers who request it for reasonable reasons.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings